Quercetin Ameliorates Diabetic Nephropathy by Reducing the Expressions of Transforming Growth Factor-β1 and Connective Tissue Growth Factor in Streptozotocin-Induced Diabetic Rats

REFERENCES

• Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care. 2000;23:B21–B29.
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, . Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861–869.
   PubMed Web of Science ®Google Scholar
• Balakumar P, Arora MK, Ganti SS, Reddy J, Singh M. Recent advances in pharmacotherapy for diabetic nephropathy: Current perspectives and future directions. Pharmacol Res. 2009;60:24–32.
   PubMed Web of Science ®Google Scholar
• Paczek L, Gaciong Z, Bartlomiejczyk I, Sebekova K, Birkenmeier G, Heidland A. Protease administration decreases enhanced transforming growth factor-beta 1 content in isolated glomeruli of diabetic rats. Drugs Exp Clin Res. 2001;27:141–149.
   PubMedGoogle Scholar
• Han DC, Hoffman BB, Hong SW, Guo J, Ziyadeh FN. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice. Am J Physiol Renal Physiol. 2000;278:F628–F634.
   Web of Science ®Google Scholar
• Umezono T, Toyoda M, Kato M, . Glomerular expression of CTGF, TGF-beta 1 and type IV collagen in diabetic nephropathy. J Nephrol. 2006;19:751–757.
   PubMed Web of Science ®Google Scholar
• Connolly SB, Sadlier D, Kieran NE, Doran P, Brady HR. Transcriptome profiling and the pathogenesis of diabetic complications. J Am Soc Nephrol. 2003;14:S279–S283.
   Web of Science ®Google Scholar
• Phan TT, Lim IJ, Chan SY, Tan EK, Lee ST, Longaker MT. Suppression of transforming growth factor beta/smad signaling in keloid-derived fibroblasts by quercetin: Implications for the treatment of excessive scars. J Trauma. 2004;57:1032–1037.
   PubMed Web of Science ®Google Scholar
• Kanter M. Protective effect of quercetin on liver damage induced by biliary obstruction in rats. J Mol Histol. 2010;41:395–402.
   PubMed Web of Science ®Google Scholar
• Huang BF, Wang W, Fu YC, Zhou XH, Wang X. The effect of quercetin on neointima formation in a rat artery balloon injury model. Pathol Res Pract. 2009;205:515–523.
   PubMed Web of Science ®Google Scholar
• Mao YQ, Liu XJ, Jiang Y, Wu HB. Effect of quercetin on the signal pathway of TGFbeta1 in activated hepatic stellate cells. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004;35:802–805.
   PubMedGoogle Scholar
• Anjaneyulu M, Chopra K. Quercetin, an anti-oxidant bioflavonoid, attenuates diabetic nephropathy in rats. Clin Exp Pharmacol Physiol. 2004;31:244–248.
   PubMed Web of Science ®Google Scholar
• Barratt J, Topham P. Urine proteomics: The present and future of measuring urinary protein components in disease. CMAJ. 2007;177:361–368.
   PubMed Web of Science ®Google Scholar
• Rosolowsky ET, Niewczas MA, Ficociello LH, Perkins BA, Warram JH, Krolewski AS. Between hyperfiltration and impairment: Demystifying early renal functional changes in diabetic nephropathy. Diabetes Res Clin Pract. 2008;82:S46–S53.
   Web of Science ®Google Scholar
• Renugadevi J, Prabu SM. Quercetin protects against oxidative stress-related renal dysfunction by cadmium in rats. Exp Toxicol Pathol. 2010;62:471–481.
   PubMed Web of Science ®Google Scholar
• Chander V, Singh D, Chopra K. Reversal of experimental myoglobinuric acute renal failure in rats by quercetin, a bioflavonoid. Pharmacology 2005;73:49–56.
   PubMed Web of Science ®Google Scholar
• Jeong HS, Park KK, Park KK, . Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin-induced diabetic rat kidney. J Korean Med Sci. 2004;19:374–383.
   PubMed Web of Science ®Google Scholar
• Ziyadeh FN. Mediators of diabetic renal disease: The case for tgf-Beta as the major mediator. J Am Soc Nephrol. 2004;15:S55–S57.
   PubMed Web of Science ®Google Scholar
• Ha SW, Kim HJ, Bae JS, . Elevation of urinary betaig-h3, transforming growth factor-beta-induced protein in patients with type 2 diabetes and nephropathy. Diabetes Res Clin Pract. 2004;65:167–173.
   PubMed Web of Science ®Google Scholar
• Wang SN, LaPage J, Hirschberg R. Role of glomerular ultrafiltration of growth factors in progressive interstitial fibrosis in diabetic nephropathy. Kidney Int. 2000;57:1002–1014.
   PubMed Web of Science ®Google Scholar
• Baowen Q, Yulin Z, Xin W, . A further investigation concerning correlation between anti-fibrotic effect of liposomal quercetin and inflammatory cytokines in pulmonary fibrosis. Eur J Pharmacol. 2010;642:134–139.
   PubMed Web of Science ®Google Scholar
• Mason RM. Connective tissue growth factor (CCN2), a pathogenic factor in diabetic nephropathy. What does it do? How does it do it? J Cell Commun Signal. 2009;3:95–104.
   PubMed Web of Science ®Google Scholar
• Nguyen TQ, Tarnow L, Andersen S, . Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83–88.
   PubMed Web of Science ®Google Scholar
• Guha M, Xu ZG, Tung D, Lanting L, Natarajan R. Specific down-regulation of connective tissue growth factor attenuates progression of nephropathy in mouse models of type 1 and type 2 diabetes. FASEB J. 2007;21:3355–3368.
   PubMed Web of Science ®Google Scholar